Related Experiment Video
Updated: Jun 7, 2025
Systemic Bacterial Infection and Immune Defense Phenotypes in Drosophila Melanogaster
Published on: May 13, 2015
Drosophila melanogaster experimental model to test new antimicrobials: a methodological approach
Maria Vidal1,2,3, Marta Arch1,3, Esther Fuentes1,3,4
1Microbiology Department, Laboratori Clínic Metropolitana Nord, Germans Trias i Pujol University Hospital (HUGTP), Badalona, Catalonia, Spain.
Abstract:
Given the increasing concern about antimicrobial resistance among the microorganisms that cause infections in our society, there is an urgent need for new drug discovery. Currently, this process involves testing many low-quality compounds, resulting from the in vivo testing, on mammal models, which not only wastes time, resources, and money, but also raises ethical questions. In this review, we have discussed the potential of D. melanogaster as an intermediary experimental model in this drug discovery timeline. We have tackled the topic from a methodological perspective, providing recommendations regarding the range of drug concentrations to test based on the mechanism of action of each compound; how to treat D. melanogaster, how to monitor that treatment, and what parameters we should consider when designing a drug screening protocol to maximize the study's benefits. We also discuss the necessary improvements needed to establish the D. melanogaster model of infection as a standard technique in the drug screening process. Overall, D. melanogaster has been demonstrated to be a manageable model for studying broad-spectrum infection treatment. It allows us to obtain valuable information in a cost-effective manner, which can improve the drug screening process and provide insights into our current major concern. This approach is also in line with the 3R policy in biomedical research, in particular on the replacement and reduce the use of vertebrates in preclinical development.
Insights
The fruit fly, Drosophila melanogaster, offers a cost-effective and ethical alternative for antimicrobial drug discovery. This model streamlines screening, reducing reliance on mammal models and aligning with the 3Rs policy.
Area of Science:
- Microbiology
- Pharmacology
- Genetics
Background:
- Antimicrobial resistance (AMR) is a growing global health threat, necessitating novel drug discovery pipelines.
- Current drug discovery relies heavily on mammal models, which are time-consuming, expensive, and ethically concerning.
- There is a critical need for efficient and ethical preclinical models to accelerate the identification of new antimicrobial compounds.
Purpose of the Study:
- To review the utility of Drosophila melanogaster (fruit fly) as an intermediary model in antimicrobial drug discovery.
- To provide methodological recommendations for optimizing drug screening protocols using Drosophila.
- To advocate for the establishment of Drosophila as a standard preclinical model in line with the 3Rs policy.
Main Methods:
- Literature review focusing on Drosophila melanogaster as a model organism for infection studies.
- Methodological analysis of drug screening parameters, including concentration ranges, treatment protocols, and monitoring techniques.
- Discussion on the advantages and limitations of using Drosophila in drug discovery.
Main Results:
- Drosophila melanogaster serves as a manageable and cost-effective model for studying broad-spectrum infection treatments.
- Established protocols can yield valuable data for improving drug screening efficiency.
- The use of Drosophila aligns with the 3Rs policy by reducing and replacing vertebrate use.
Conclusions:
- Drosophila melanogaster presents a viable and efficient model for accelerating antimicrobial drug discovery.
- Optimized screening protocols in Drosophila can significantly enhance the identification of potential drug candidates.
- Adoption of Drosophila models supports ethical research practices and addresses the urgent need for new antimicrobials.
